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Purpose. To investigate the in vitro in vivo correlation of a sustained release formulation for human
growth hormone (hGH) based on hydroxyethyl methacrylated dextran (dex-HEMA) microspheres in
Pit-1 deﬁcient Snell dwarf mice and in healthy human volunteers.
Materials and Methods. A hGH-loaded microsphere formulation was developed and tested in Snell
dwarf mice (pharmacodynamic study) and in healthy human volunteers (pharmacokinetic study).
Results. Single subcutaneous administration of the microspheres in mice resulted in a good correlation
between hGH released in vitro and in vivo effects for the hGH-loaded microsphere formulation similar
to daily injected hGH indicating a retained bioactivity. Testing the microspheres in healthy volunteers
showed an increase (over 7–8 days) in hGH serum concentrations (peak concentrations: 1–2.5 ng/ml). A
good in vitro in vivo correlation was obtained between the measured and calculated (from in vitro
release data) hGH serum concentrations. Moreover, an increased serum concentration of biomarkers
(insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3) was found again indicating that
bioactive hGH was released from the microspheres.
Conclusions. Good in vitro in vivo correlations were obtained for hGH-loaded dex-HEMA micro-
spheres, which is an important advantage in predicting the effect of the controlled drug delivery product
in a clinical situations.
KEY WORDS: dex-HEMA microspheres; hGH; dextran; in vitro in vivo correlation.
INTRODUCTION
Since the introduction of recombinant human Growth
Hormone (hGH) in 1985, the treatment of patients suffering
from pediatric growth hormone deﬁciencies has improved
considerably. However, hGH replacement therapy still
suffers from the burden of daily injections, which negatively
affects patient compliance and comfort. The availability of
injectable systems, delivering hGH with a controlled rate
over a period of 1 week to 1 month would be a signiﬁcant
improvement of the current daily treatment.
Several parenteral sustained release systems for the
controlled delivery of growth hormone have been investi-
gated (1–6). The best known hGH sustained delivery system
consists of polylactide-co-glycolide acid (PLGA) based
microspheres, containing up to 22.5 mg hGH per injection,
which was designed for monthly and bi-weekly treatment of
growth hormone deﬁcient patients (2,7,8).
In general, PLGA microsphere systems have several
drawbacks, such as a high burst release of the active
ingredient, the use of organic solvents for the microsphere
preparation and acidiﬁcation of the PLGA matrix during
release of the active ingredient which can lead to protein
aggregation when no stabilizers are added (9–12). High burst
release results in the loss of signiﬁcant amounts of active
during a short period of time and reduces the efﬁcacy of the
formulation. Importantly, the release of aggregated protein
may result in an immunogenic response (13,14). Especially
for proteins these issues will limit successful application of
PLGA as controlled release matrix.
Hydrophilic matrices such as hydrogels are generally
gentler for sensitive proteins than hydrophobic matrices
such as PLGA (15,16). We have developed hydrogel
microspheres, consisting of degradable networks of cross-
linked dextran (17,18). Therapeutic proteins can be physi-
cally entrapped in the network and released by degradation
of the network upon administration. Typical release proﬁles
of proteins from these hydrogels range from zero-order to
sigmoidal with a duration of typically 1 to 4 weeks (18,19).
Details on the preparation and properties of dex-HEMA
microspheres have been described previously (18,20–27).
At present, no information is available about the in vitro
in vivo correlation (IVIVC) of protein-loaded dex-HEMA
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in vitro release tests can serve as a guide to formulation
development.
In this study, we designed an hGH-loaded dex-HEMA
microsphere formulation which releases the protein for 7
days. The IVIVC of this formulation in Pit-1 deﬁcient
Snell dwarf mice and in healthy human volunteers was
investigated. In dwarf mice, increase in body length and in
body weight were measured after a single subcutaneous
injection of hGH loaded dex-HEMA microspheres and
compared with data from daily subcutaneously injected
solutions of hGH in saline during a period of 4 weeks. In a
clinical setting, hGH serum concentrations were compared
to the calculated theoretical serum concentrations, based
on the in vitro release proﬁle of hGH after a single
subcutaneous injection with hGH loaded dextran micro-
spheres. To investigate the biological activity of released
hGH serum levels of IGF-1 and IGFBP-3, two biomarkers
for hGH, were also monitored.
MATERIALS AND METHODS
Chemicals. Poly(ethylene glycol) (PEG) 10 kDa and
potassium peroxodisulfate (KPS) were obtained from Merck,
Darmstadt, Germany. N,N,N¶,N¶-tetramethylethylenediamine
(TEMED), sucrose and carboxymethylcellulose were pur-
chased from Fluka (Buchs, Switzerland). Hydroxyethyl
methacrylate derivatized dextrans (dex-HEMA) with a
degree of HEMA substitution (DS, number HEMA groups
per 100 glucose units) of 12, 16 and 20 were synthesized and
characterized according to Van Dijk-Wolthuis et al. (17) and
obtained from Polymer Service Center Groningen (PSCG,
Groningen, the Netherlands). HGH-190 (Somatogen
\),
which is a truncated form (lacking one phenylalanine
residue) of the natural human growth hormone) was kindly
supplied by Biotechna Sicor Inc. (Irvine, CA, USA).
Microsphere Preparation
Formulation Development. Different batches dex-HEMA
microspheres were prepared at 5 g scale with various DS, KPS
concentrations and protein load (Table I). The preparation
procedure was based on the water-in-water emulsion technique
as described elsewhere (18,21). In detail, for microspheres with
an initial water content of 50% and a protein load of 3%
w/w (weight hGH/weight dex-HEMA), 61 mg of dex-HEMA
was dissolved in 0.6 ml hGH solution (3.2 mg/ml hGH in
10 mM phosphate buffer pH 7.4 containing mannitol and
glycine) and the resulting solution was freeze dried
(Lyostar, FTS Systems, Inc. Stone Ridge, USA). Next, the
obtained cake was hydrated in 4.9 g of a 27% w/w PEG
solution in 25 mM phosphate buffer pH 7.0. The mixture was
vortexed for 1 min and subsequently 100 ml of a TEMED
solution [20% (v/v), pH neutralized with 4 M hydrochloric
acid] was added, followed by vortexing for 20 s. Then,
180 ml KPS (concentration 50 mg/ml in PBS) was added, the
emulsionwasshakengentlyandallowedtopolymerizefor1hat
room temperature. The formed microspheres were washed ﬁve
times with 5 ml 25 mM phosphate buffer pH 7.4.
Animal Trial Material (ATM). For the animal trial, two
different batches of hGH-loaded microspheres (dex-HEMA
DS16, initial water content of 50% and target protein loading
of 10% hGH w/w dry weight (ATM 1) or initial protein
loading of 10% hGH w/w dry weight (ATM 2)) and placebo
microspheres (dex-HEMA DS16 initial water content of
50%) were prepared. The microspheres were prepared at
30 g scale (corresponding with 0.4 g dry weight of micro-
spheres). Apart from scale and amounts of raw materials and
reagents adjustments, the preparation procedure of the micro-
spheres was the same as described in the previous section.
Only, the preparation procedure of the microspheres of
ATM2 slightly deviated from the standard preparation
procedure. These microspheres were obtained by homogeni-
zation of the dex-HEMA/PEG emulsion for 4 min at 10,000
psi with an Avestin C5 homogenizer (ATA scientiﬁc, Lucas
Heights, Australia), prior to polymerization. The micro-
Table I. Characteristics of the Different hGH Containing Dex-HEMA Formulations
Formulation DS
Initial Protein Loading
(% w/w)
KPS Concentration
(mg/ml)
Recovery (%)
Time to Release
90% (days) Burst (%)
Q90%
a Q7 days
a e10%
a
1 12 3 50 87 j 5.5 j 11 j
2 12 10 13 96 + 3.7 j 32 j
3 12 16 50 97 + 4.3 j 28 j
4 12 20 50 100 + 3.1 j 40 j
5 16 3 50 84 j 6.9 j 8+
6 16 10 50 91 + 7.7 + 9 +
7 16 20 13 94 + 6.6 j 11 j
8 20 3 13 72 j 9.9 + 10 j
9 20 3 50 86 j 12.4 + 12 j
10 20 20 50 95 + 7.6 + 14 j
a+ and j indicate whether the formulation requirements are met (+) and or not (j). The values are the mean of two independent
measurements that deviated less than 10%.
Percentage of aggregation was not investigated in this study as in a previous study, it was demonstrated that formulation parameters did not
effect the percentage aggregation of the released hGH (27).
2240 Vlugt-Wensink et al.spheres were washed with water by ﬁve centrifugation (3,500
rpm, 20 min) and washing steps (90 ml water). Finally, the
microspheres were resuspended in 5.5 ml 25 mM phosphate
buffer pH 7.4 also containing 3% (w/v) carboxy methyl
cellulose (CMC) to prevent sedimentation of the micro-
spheres and freeze-dried.
Clinical Trial Material (CTM). The hGH loaded dex-
HEMA microspheres for the study in volunteers were
prepared at a 1 kg process scale (12 g dex-HEMA). Except
for scale adjustment of amounts of raw materials and
reagents, microspheres (dex-HEMA DS16, 50% initial
water content, 10% hGH w/w dry weight) were prepared
essentially according to the procedure described above.
Brieﬂy, the PEG/dex-HEMA/buffer mixture was emulsiﬁed
for 55 min at 1,500 rpm in an autoclavable 2-l jacketed
Bioreactor unit equipped with bafﬂes and a three bladed
impeller (4.5 cm in diameter; Applikon B.V., Schiedam, the
Netherlands). Next, 4 ml TEMED solution [20% (v/v), pH
neutralized with 4 M hydrochloric acid] was added and
stirring was continued for 5 min. The stirring rate was set to
500 rpm and 2.7 ml of 50 mg/ml KPS-solution was added.
The stirring was stopped after 5 min and the emulsion was
incubated at room temperature for 60 min to polymerize the
dextran grafted HEMA groups. Removal of PEG, KPS and
TEMED was performed by crossﬂow ﬁltration with a
FiberFlo hollow ﬁber capsule ﬁlter (0.22 mm: Minntech,
Mineappolis, USA) using 5.5 l 5 mM phosphate buffer pH
7.4 containing 3% w/w sucrose. The microspheres were
suspended in 450 ml 5 mM phosphate buffer pH 7.4
containing 3% w/w sucrose and concentrated over the ﬁlter
to 500 ml. The resulting microsphere suspension was
pumped into 20 ml vials (7.3 g per vial) and freeze-dried
(Lyostar, FTS Systems, Inc. Stone Ridge, USA). The hGH
content of the microspheres was determined by amino acid
analysis (Ansynth, Roosendaal, The Netherlands). Brieﬂy,
about 1 g of microsphere suspension (10 mg microspheres/g)
was incubated with HCl (6 M) by incubation at 110-Cf o r
22 h to hydrolyze the matrix and the protein. The sample
solution was mixed with internal standard solution (Sig-
ma, USA) and analyzed for amino acid concentration
with an amino acid analyzer (Biochrom 20, Pharmacia,
Uppsala, Sweden), using a weakly acidic cation exchange
column (Bio20 Lithium, 250 4.6 mm, Ultropac 8 Li-
form, Pharmacia, Uppsala, Sweden).
To ensure the sterility of both the animal and clinical trial
material, the microspheres were produced aseptically. Prior to
use, all solutions were pumped through a sterile Millipak 200
ﬁlter into the vials. All equipment was autoclaved before
use (30 min 121-C, Sauter autoclave; Sauter AG, Sulgen,
Switzerland) and vials were heated for 4 h at 250-C.
Average particle diameters and size distributions of the
microspheres were measured with a Malvern Mastersizer
2000 (Malvern instruments Ltd, Worcestershire, United
Kingdom) with water as diluent.
In Vitro Release Characteristics of hGH Microspheres
Freeze dried microspheres (40 mg) were hydrated in 5 ml
25 mM phosphate buffer pH 7.4 at 37-C. At different time
points, the microspheres were centrifuged for 5 min at
3,200 g; 3 ml supernatant was removed and replaced by 3
ml of the same buffer. The hGH concentration in the samples
was determined by GPC (see next section). The burst release
is deﬁned as the percentage of the encapsulated amount hGH
released after 7 h of incubation. The recovery is deﬁned as
percentage of the total amount of released hGH (after 4–20
days; dependent on the formulation) divided by the encap-
sulated amount hGH. The encapsulated amount of hGH in
the microspheres was determined by summation of the total
amount released from the microspheres and the amount of
hGH present in the microspheres after the release period
(after 4–20 days; dependent on the formulation) determined
with nitrogen analysis (see nitrogen analysis).
Size Exclusion Chromatography. High performance size
exclusion chromatography (HP-SEC) was used to determine
the hGH concentration in the release samples. The HPLC
system consisted of a pump series 200, a vacuum degasser series
200, an autosampler series 200, a column LC 101 oven, and a
UVdetectorseries200(allPerkinElmerInstruments,Norwalk,
USA), thermostated (35-C) Thosohaas TSKgel G300SWXL
column and a Thosohaas TSKgel SWXL guardcolumn (Mont-
gomeryville, PA, USA). The ﬂow rate was 0.7 ml/min and a
mobile phase containing phosphate buffer (64 mM, pH 7.0)
and 3% (v/v) isopropanol was used. The chromatograms were
recorded and analyzed with the Totalchrom data acquisition
system (Perkin Elmer Instruments, Norwalk, USA).
Nitrogen Analysis. The amount of protein present in the
microspheres (corrected for the nitrogen content in placebo
microspheres) at the end of the release period (after 4–20
days; dependent on the formulation) was determined. by
nitrogen anlaysis. The samples (500 ml) were injected using
an autoinjector (ELS 2100) into a nickel boat, which was
subsequently transported into the furnace tube TN 3000. The
analyzer was equipped with a cold trap TX/TS module and a
UV detector (both thermo Euroglass corp. Delft, Holland).
The argon ﬂow was set at 340 ml/min, the oxygen ﬂow was set
at 15 ml/min and the ozonator was set at 110 ml/min. The
temperature of the furnaces was set at 1,000-C, while
temperature of the NOx scrubber was set at 320-C. A cali-
bration curve was obtained injecting 500 ml of an aqueous
glycine solution (0.1–10 mg/ml). The hGH-190 concentration
was calculated by assuming it contains 16.7% w/w nitrogen
(28). The data were recorded and analyzed with the data
acquisition system of Thermo Euroglass DIN 38409 (Thermo
Euroglass corp. Delft, Holland).
Animal Experiments
Pit-1 deﬁcient Snell dwarf mice were bred and kept
under standardized laboratory conditions (24-C, relative
humidity 60%). Dwarfs were bred by mating heterozygous
females (+/dw) to dwarf males (dw/dw), rendered fertile by
treatment with 1 mg L-thyroxine and 50 mg prolactin 5 days a
week for at least 4 weeks. After weaning at 4–5 weeks, the
dwarfs were maintained on a diet of commercial food pellets,
supplemented with a mixture of milk powder, wheat embryo,
and raw egg (1:2:2) suspended in 10% glucose in water (29).
All animals were weighed and their length was measured
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male and female dwarfs turned out to be similar, groups
contained both males and females (age 6–8 weeks).
Study Procedure and Assay Methods
The dwarf mice were selected to obtain equal initial
means and standard deviations for length and weight and
an equal distribution over both sexes and age at the start
o ft h ee x p e r i m e n t .T h em i c ew e r ed i v i d e do v e rﬁ v eg r o u p s
each consisting of ﬁve animals. Group 1 received 0.1 ml
phosphate buffered saline (PBS for 5 days a week for 4
weeks, once daily); group 2, hGH-190, 8.3 mg dissolved in
0.1 ml saline for 5 days a week for 4 weeks, once daily
(total dose of hGH administered 166 mg); group 3 received
only at the start of the experiment 0.1 ml of a hGH loaded
dex-HEMA microsphere (ATM1; releasing 232 mgh G H )
suspension in saline; group 4 received only at the start of
the experiment 0.1 ml of a hGH loaded dex-HEMA
microsphere (ATM2; releasing 156 mg hGH) suspension
in saline.
Weekly, body length and weight were measured. Local
reactions of the injected microspheres were assessed during
the course of the experiment and just before the animals
were killed by decapitation, 4 weeks after the start of the
experiment, by two independent researchers. Four weeks
after the start of the experiment and 2 h after the last in-
jection of animals from groups 1 and 2 all animals were killed
by decapitation under etheranaesthesia. Blood was collected,
and the sera were pooled per group. To investigate the
formation of hGH ntibodies, sera were incubated overnight
at 4-C with
125I-labeled-hGH [obtained as described by
Salacinski et al. (31) and puriﬁed by chromatography on
Sephadex G-50 followed by Sephadex G-100 (32)] at
different dilutions. Separation of bound and free hormone
was performed by adding 100 ml Sac-Cel anti-rat IgG coated
cellulose suspension (Immunodiagnostic Systems, Boldon
UK). After 30 min of complexation at room temperature,
0.5 ml distilled water was added, and the samples were
centrifuged at 10,000 g for 4 min. Radioactivity in the
pellets was counted in a Packard g-counter.
Clinical Trial
Subjects
Subjects were enrolled at the Clinic of Cardiology in
Tartu, Estonia, for a single-dose pharmacokinetic study in
healthy elderly volunteers. Institutional Review Board
approval was obtained and patient signed informed con-
sent forms were obtained before screening. Healthy men
between 50 and 80 years were recruited for this study. All
subjects passed pre-study physical examination, laboratory
tests and ECG. Entry criteria included body mass index
between 22 and 27 kg/m
2, peak growth hormone level <3
mg/l and IGF-1 level <280 mg/l and absence of indications of
major diseases. Subjects were excluded if they had a history
of diabetes mellitus, or active thyroid function abnormalities,
or active hepatic, renal, metabolic or endocrine diseases.
Study Treatment
After a 2-day baseline period, ten volunteers received
one dose of hGH loaded dex-HEMA microspheres for-
mulation (age, 62T7 years; body weight, 82T13 kg; BMI,
27T3 kg/m
2; peak growth hormone level <3 mg/l and IGF-1
level <280 mg/l) equivalent to 14 mg hGH. Each subject
received the above treatments by subcutaneous injection in
the abdomen. The dose was administered in volumes of
approximately 1.1 ml (75 mg microspheres/ml) by four
subcutaneous injections, each at a different abdominal site.
Study Procedure and Assay Methods
Subjects were screened for eligibility within 3 weeks
prior to the institutionalisation period. After fulﬁlling all
inclusion and exclusion criteria subjects were institutionalised
from the evening before dayj2 up to the morning after the
day study medication has been administered (day 2).
Hereafter subjects returned to the institute on day 3, 5, 7, 8,
9, 10, 11, 12, 14, 24 and 38. Subjects returned for a last follow-
up visit to the institute on day 90 (T3 days). Growth hormone
serum levels were measured during screening, at baseline and
after treatment up to day 38. From day 3 to 38 after drug
administration, three blood samples were taken at 30-min
intervals, on each assessment day. Endogenous growth
hormone is released from the pituitary in a pulsatile fashion
[short peak every 2 h (33)], and a single growth hormone
sample might coincide with an endogenous growth hormone
peak, thus masking the growth hormone levels due to the
hGH loaded dex-HEMA microsphere treatment. To mini-
mize this risk, three samples were taken as described, and the
lowest growth hormone value of each triplet sample was
taken to account for endogeneous hGH spikes. On the basis
of this minimum-out-of-three approach, mean growth hor-
mone proﬁles for all treatment groups were obtained.
The collected blood samples for the determination of
growth hormone, IGF-1 and IGFBP-3 were collected using
4 ml clot-activator tubes, and later centrifuged for 10 min
at 1,100–1,300 g to collect the serum. Serum was stored
at j20-C until analysis. Samples were labeled by a bar code,
which contained the subject number, sample number, study
day and study code. Analysis were performed by HTI
Laboriteenuste AS (Hiiu 44, Tallinn, Estonia). Serum con-
centrations of hGH, IGF-1 and IGFBP-3 were determined by
a two-site chemiluminescent enzyme immunometric assay
standard kit (Immulite, Diagnostic Products Corporation,
Los Angeles, USA) using an IMMULITE 2000 Analyzer
(Diagnostic Products Corporation, Los Angeles, USA).
In Vitro In Vivo Correlation
The serum hGH concentration in humans as function of
time was calculated with Modelmaker 4 (AP Benson, Oxford-
shire, UK) from the in vitro release data, using a one-
compartment linear model (34). In this model, blood is
considered as a single compartment and the serum concen-
tration as function of time is calculated from the absorption
of subcutaneous hGH into the blood and the hGH elimina-
tion from the blood. Furthermore, it is assumed that equi-
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extravascular tissues is rapidly formed, and that the excretion
and absorption follow ﬁrst order kinetics. In Fig. 1a
schematic overview is given of the calculations in Model-
maker 4. Brieﬂy, from the in vitro release data, the amount of
hGH released subcutaneously per unit of time was calculat-
ed. From these data, following ﬁrst order reaction kinetics,
the rate of hGH absorption (mg hGH/unit of time) into the
blood was calculated, using the absorption rate constant in
humansderivedfromabsorptionhalflifeinhumans(t1/2,a=0.7h)
obtained by Jorgenson et al. for subcutaneous administration of
hGH (35) and a bioavailability of 75% (36)u s i n g :
dA1
dt
¼ Rt ðÞ B   ka   A1 ð1Þ
Where, A1 is the amount of hGH present subcutaneously, R(t)
is the amount of hGH released from the microspheres per unit
of time, ka is the absorption rate constant, B is the bioavail-
ability of hGH.
Again following ﬁrst order reactions kinetics, the
amount of hGH in the serum as function of time was
calculated from the absorption rate data using the elimina-
tion rate constant in humans (derived from elimination half
life in humans t1/2,el=12 min; (35) according to:
dA2
dt
¼ B   ka   A1   kel   A2 ð2Þ
Here A2 is the amount of hGH present in serum and kel is the
elimination rate constant. Finally, the serum hGH concentra-
tion followed from dividing this amount by the average
distribution volume (Vd) of the elderly male human volunteers
(70 ml/kg body weight). The in vitro in vivo correlation was
evaluated by comparing the calculated serum concentration
time data to the measured serum concentration time data.
RESULTS
Formulation Development
Figure 2 shows some typical cumulative release curves of
hGH from these dex-HEMA microspheres. The results of all
formulations are summarized in Table I. Figure 2 shows that
hGH was released with almost zero order kinetics from dex-
HEMA microspheres for 5–15 days, dependent on the
formulation. This ﬁgure also shows that the time to release
more than 90% of hGH increased with an increasing DS and
decreasing protein loading, which is consistent with previous
observations (18,26). The results in Table I show that the
time to release 90% of hGH decreased with increasing KPS
concentration (e.g. compare formulation 8,9). Furthermore,
the burst release ranged between 8 and 40% of the loading
and increased with increasing protein loading (e.g. compare
formulation 1,3,4). The recovery of hGH ranged respectively
between 71 and 100% and no obvious effects of KPS
concentration, loading and DS on recovery were found.
In Table I, the formulations are scored for the preferred
characteristics (time to release 90% >7 days, burst release
<10%, recovery >90%). Only formulation 6 meets all the
requirements. Therefore, the processing parameters identi-
ﬁed for the preparation of this formulation were used for the
preparation of microspheres for both the animal trial (ATM)
and the clinical trial (CTM) microsphere batches.
Formulation and In Vitro Release Characteristics of Animal
Trial Material (ATM) and Clinical Trial Material (CTM)
In Table II, the characteristics of the dex-HEMA
microspheres prepared for the animal trial and for the
clinical trial are presented. The homogenization of the
emulsion resulted in substantially smaller particles than
without homogenization (compare the median volume diam-
eter of ATM1 and ATM2; d(0.5)=19.7 mm and d(0.5)=4.6 mm,
respectively). For the preparation of the CTM batch, no
homogenization was used, which resulted in the formation of
hGHloadeddex-HEMAmicrosphereswitha[d(0.5)=18.0 mm].
In Fig. 3, the cumulative release proﬁles of hGH from
the ATM1 and ATM2 batches are shown. For both batches,
near zero-order release of hGH was observed for 9 days.
Both ATM1 and ATM2 showed a small burst release of
8 and 10% respectively (Table II). A recovery of 66 and
100% was obtained for the homogenized (ATM2) and the
not homogenized batch (ATM1; Table II), respectively.
Figure 4 shows the release curve of the clinical trial material
(CTM). In contrast to the microspheres prepared at 30 g
scale, microspheres produced in the bioreactor at a 1 kg scale
Fig. 2. Cumulative release of hGH from DS 12 (closed squares, open
squares), and 20 (closed triangles, open triangles) microspheres. The
initial water content was 50% and the protein load was 3% (closed
symbols) and 20% (open symbols). The values are the average of two
independent measurements and deviated less than 10%.
Subcutane Blood
(Vd)
in vitro hGH
release from
microspheres
Elimination
kel ka
predicted
hGH serum
concentration
Fig. 1. Schematic overview of model used to predict the in vivo
serum concentration of hGH.
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approximately 3 days.
Dwarf Mice Study
In Fig. 5 the growth curves of dwarf mice injected with
an hGH solution, hGH-loaded microspheres (ATM1,
ATM2), and PBS are shown. These ﬁgures show that after
repeated injection of an hGH solution as well as a single
subcutaneous injection of hGH loaded dex-HEMA micro-
spheres, both weight and length of the mice steadily increases
in time (over a period of 28 days for mice injected with single
subcutaneous injections and over a period of 14 days for mice
injected with ATM1,2). In Fig. 6 the cumulative in vitro
release of hGH (ATM1, ATM2) and the cumulative admin-
istered amount of hGH (control) are plotted against the
observed pharmacodynamic effect (increase in body length).
The Fig. 6a shows that the pharmacodynamic effect almost
perfectly follows the in vitro release of hGH. Importantly,
Fig. 6b demonstrates that the growth per mg of hGH is
comparable both for hGH loaded dex-HEMA microspheres
and for the repeated injection of an hGH solution.
Although hGH-190 is active in Snell dwarf mice, it is a
foreign protein for mice, and therefore can induce the
formation of antibodies and give rise to local site effects.
Figure 7 indeed shows that 4 weeks after administration of
hGH, hGH-speciﬁc antibodies were detected in the sera of
the mice. In this ﬁgure the binding of radioactively labeled
hGH (
125I-hGH) to formed hGH antibodies present in the
pooled sera of mice is shown. HGH-speciﬁc antibodies were
found 4 weeks after the start of treatment with hGH. The
ED50 for the binding of
125I-hGH to antibodies in the serum
was obtained at serum dilutions of approximately 200 , 800 
and 1,200  for free hGH, hGH released from microspheres
from ATM1 and ATM2 respectively. Apparently, both free
hGH and hGH released from the microspheres evoked an
immune response in these mice. Mice that had received the
smaller ATM2 microspheres showed higher antibody levels
than mice injected with the larger ATM1 microspheres.
Moreover, a higher incidence of palpable local injection site
reactions for ATM2 was found; one out of ﬁve mice
developed an injection site reaction after injection with
ATM1, while ATM2 caused injection site nodule formation
in all mice.
Table II. Characteristics of ATM and CTM hGH-Loaded Dex-HEMA Microsphere Batches
Formulation
Median Volume-Based
Diameter [d(0.5); mm] Recovery (%)
Time to Release
90% (days) Burst (%)
hGH loaded dex-HEMA
microspheres (ATM1)
19.7 98 9.0 8
hGH loaded dex-HEMA
microspheres (ATM2)
4.6 66 8.8 10
hGH loaded dex-HEMA
microspheres (CTM)
18.0 100 8.5 1
The values are the average of two independent measurements that deviated less than 10%.
Fig. 3. Cumulative release of hGH from dex-HEMA microsphere
(DS 16, initial water content 50%, initial protein loading 10% w/w)
batches prepared without homogenization (ATM1, Table II; closed
squares) and with homogenization of the emulsion prior to polymer-
ization (ATM2, Table II; closed triangles). ATM1 and ATM2 were
used in the animal study. The values are the average of two
independent measurements and deviated less than 15%.
Fig. 4. Cumulative release of hGH from dex-HEMA microspheres
(DS 16, initial water content 50%, initial protein loading) used in the
clinical study (CTM, Table II). The values are the average of two
independent measurements and deviated less than 5%.
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Figure 8 shows the serum hGH concentration in male
elderly volunteers after subcutaneous administration of dex-
HEMA microspheres. A short-lived rise in serum growth
hormone concentration was observed directly after adminis-
tration. Hereafter, hGH concentrations started to rise from
day 2, peaking and leveling off approximately on days 7 and
8 after injection. The peak hGH serum concentrations were
approximately between 1.0 and 2.5 ng/ml all subjects. Also
shown in this ﬁgure are the serum concentration time data
calculated from the in vitro release curve of hGH from the
dex-HEMA microspheres of the clinical trial material using
the model described in the materials and methods (Fig. 4).
The calculated serum concentration is in good agreement
with the measured average serum hGH concentration.
The serum concentrations of biomarkers IGF-1 and
IGFBP-3 are shown in Figs. 9 and 10. The average serum pro-
ﬁles followed the average serum growth hormone proﬁle well.
DISCUSSION
To save protein, the primary screening for a suitable
protein loaded microsphere formulation is generally per-
formed with microsphere formulations prepared at small-
Fig. 5. Cumulative % increase in body length of dwarf mice during 4
weeks after sc injection of saline (open squares), hGH 8.3 mg/per day
for 28 days (open triangles), ATM1 microspheres (closed squares)
and ATM2 microspheres (closed triangles). MeanTS.E. (n=5).
Curves are signiﬁcant different (P<0.05).
Fig. 6. a In vitro in vivo correlation between cumulatively adminis-
tered/released hGH (open symbols) and cumulative increase in body
length (closed symbols) for hGH 8.3 mg/per day (open triangles,
closed triangles), microspheres of ATM1 (open squares, closed
squares) and microspheres ATM2 (open circles, closed circles) and
b cumulatively administered/released hGH vs cumulative increase in
body length for hGH 8.3 mg/per day (closed triangles), microspheres
of ATM1 (closed squares) and microspheres ATM2 (closed circles).
Fig. 7. Binding of
125I-hGH to hGH-antibodies present in sera of
Snell dwarf mice having received a single injection microspheres of
ATM1 (closed squares) and microspheres of ATM2 (closed triangles)
and daily injection of saline (open squares) or daily injection of a
solution containing 8.3 mg hGH-190 (open triangles).
Fig. 8. Measured hGH concentration in serum of human volunteers
after administration of CTM microspheres, (closed triangles) and
hGH concentration in serum (dotted line) calculated from the in vitro
release of hGH using the model as described in the materials and
methods. MeanTS.E. (n=10).
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preparation at larger scales is necessary. Differences between
process parameters (such as stirring speed, process time) at
small scale and at larger scales sometimes induce differences
in microsphere characteristics. In this study, microsphere
characteristics were initially not affected by preparation at
5 g scale or 30 g scale (ATM1). However, introduction of
an extra homogenization step in the emulsiﬁcation of
dex-HEMA and PEG prior to the polymerization of the
dex-HEMA at 30 g scale (ATM2) resulted in smaller
microspheres [d(0.5)=4.6 mm ATM2; d(0.5)=19.7 mm ATM1;
Table II] with a low recovery of hGH (66%; Table II). As
previously observed, higher shear forces (here induced by
homogenization with a turrax) applied during emulsiﬁcation
ﬁnally results in smaller microspheres (21). The low recovery
of hGH from the microspheres prepared with the extra
homogenization step (ATM2, Table II) is likely also caused
by the higher shear forces which might induce irreversible
denaturation of the protein resulting in the formation of
aggregates, which are subsequently encapsulated in the
microspheres. Importantly, the clinical material (CTM batch,
Table II) showed quantitative recovery of hGH.
The microspheres produced in the bioreactor at a 1 kg
scale (CTM batch) had a more sigmoidal release proﬁle with
a delay of approximately 3 days (Fig. 4), while microspheres
prepared at 30 g scale (ATM1,2) had a zero-order release
proﬁle (Fig. 3). This difference is attributed to the differences
in process time (one h emulsiﬁcation time for the production
of the CTM material; 1 and 5 min emulsiﬁcation time for
respectively ATM1 and ATM2). It is known that PEG and
dextran can cause precipitation of hGH (6,27,37). An
emulsiﬁcation time of 1 h might result in the formation of
large precipitates, which were subsequently encapsulated in
the microspheres. Previously, it was shown that protein
precipitates entrapped in dex-HEMA microspheres, as once
sufﬁcient crosslinks are hydrolyzed, ﬁrst the precipitate needs
to dissolve before the dissolved protein molecules can be
released, which results in a delayed release for especially for
large precipitates (26,27).
The pharmacodynamic effects of the hGH-loaded dex-
HEMA microspheres (ATM) were assessed in Snell dwarf
mice. The animal study was designed in such a way that
without the performance of an extensive PK-study (take
blood samples to investigate serum hGH or biomarker (IGF-
1 IGFBP3 concentration) the effectiveness of the tested
formulation could be screened easily by measuring the increase
in body growth of the mice. The validity of the dwarf mouse as
a model for studying growth was previously demonstrated by
van Buul-Offers and Van den Brande (38,39).
Figure 5 clearly demonstrate that administration of hGH
containing microspheres induces a dose dependent increase
in both body length. Fig. 6a demonstrates that there is a good
correlation between the amount of released hGH and the
pharmacodynamic effects as the increase in body length
almost perfectly follows the in vitro release curves. Further-
more, Fig. 6b shows that hGH released from dex-HEMA
microspheres is as effective as hGH administered via daily
injections as there is no difference between growth response
to a certain amount hGH administered by single daily
injection of a solution of hGH and to the same amount of
hGH released from either small microspheres (ATM2) or
large microspheres (ATM1). This indicates that released
hGH has mainly retained its bioactivity.
The microsphere formulations induced formation of
antibodies in the mice. The highest antibody levels were
observed after administration of small microspheres (batch
ATM2). In addition, a higher incidence of palpable local
injection site reactions was observed after the administration
microspheres from this batch than after the administration
large microspheres (batch ATM1). These observations might
be ascribed to the size of the microspheres [d(0.5)=4.6 mm
ATM2; d(0.5)=19.7 mm ATM1]. Microspheres smaller than
10 mm in diameter can be phagocytosed (Anderson and
Shive, 1997). The observed higher antibody response after
administration of ATM2 might therefore indicate that these
microspheres were phagocytosed by antigen presenting cells.
In addition, for ATM2 a recovery of 66% was obtained
(Table II), these microspheres might contain more hGH
aggregates, which might be the cause of the higher antibody
response. Importantly, antibody formation does not affect
the growth pattern, which suggests that the antibodies were
not neutralizing.
Figure 8 shows that the shape of the serum hGH curve
follows the cumulative in vitro release proﬁle well, demon-
strating a good in vitro in vivo correlation after subcutaneous
Fig. 9. Serum concentration IGF-1 after administration of CTM
microspheres. MeanTS.E. (n=10).
Fig. 10. Serum concentration IGFBP-3 after administration of CTM
microspheres. MeanTS.E. (n=10).
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elderly male human volunteers. The delay observed in the in
vitro release curve is also observed in the average serum
hGH concentration in the ﬁrst 3 days. The curve of the
calculated hGH serum concentration was in good agreement
with the measured hGH serum concentration (Fig. 8). The
short-lived rise in serum human growth hormone serum
concentration is probably caused by a small amount of non-
encapsulated hGH in the hGH loaded dex-HEMA micro-
sphere formulation. It should be noted that Fig. 4 does not
show burst release as the microspheres were washed to
remove the carboxy methyl cellulose before starting the in
vitro release and therefore, small amounts hGH retrieved in
the wash fractions were not included in the vitro release
proﬁle. The short elimination half-life of hGH [12 min; (40)]
parallels the rapid disappearance of this observation.
Figures 9 and 10 show that the serum concentration of
the biomarkers IGF-1 and IGFBP-3 followed the hGH
serum concentrations. Generally, growth hormone exposure
induces hepatic IGF-I production by increasing transcrip-
tion of IGF-I mRNA (41). Since this is not a rapid process,
the serum levels of IGF-1 do not follow the pulse in hGH
serum levels, but instead the serum levels were paralleled
by a delayed (õ36 h) increase in IGF-1 and IGFBP-3 that
leveled out to correlate to average hGH levels. IGFBP-3
is the major carrier of IGFs in serum. More than 90% of
IGF-1 and IGF-2 is bound to IGFBP-3 (42). IGFBP-3 may
provide a storage pool for IGF-1 and may be involved in the
transport of IGF-1 to tissues. Serum concentrations of
IGFBP-3 are fairly constant throughout the day and are
controlled by hGH and IGF-1 levels (43). The average
serum proﬁles IGF-1 and IGFBP-3 followed the average
serum growth hormone proﬁle well, which suggests the
preservation of bioactivity of released hGH from micro-
spheres. Moreover, IGF-1 is considered the main driver for
growth promotion (44,45). Generally the hGH dose applied
in this study (40 mgk g
j1 day
j1) may not be considered
optimal for growth stimulation (50–100 mgk g
j1 day
j1).
Nevertheless, here a 6-day period with average IGF-1 levels
of more than 200 ng/ml was observed, which may be
sufﬁcient for growth promotion (46).
In conclusion, a strong correlation between in vitro
release and pharmacodynamic or pharmacokinetic effects is
important to predict the effect of a controlled drug delivery
formulation in a clinical situation. It allows prediction of
clinical pharmacokinetics with in vitro data, and it gives more
robustness to the protein delivery system. The good in vitro
in vivo correlation is therefore an important advantage of
dex-HEMA based microspheres as a parenteral protein
delivery system.
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